Evaluate the Efficacy and Safety of KI1106 in Patients Whose TG Level is Not Adequately Controlled With Atorvastatin Calcium Monotherapy While LDL-C is Properly Controlled

NCT03482180 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

215

Enrollment

INDUSTRY

Sponsor class

Conditions

Dyslipidemias

Interventions

DRUG: KI1106 4g, QD
DRUG: Atorvastatin Calcium 20mg, QD

Sponsor

Kuhnil Pharmaceutical Co., Ltd.